Alexander E.
- Country
- Austria
- Department
- Department of Internal Medicine I
Research Overview
- Efficacy and Safety of Risankizumab in Maintenance and Long-term Extension for Moderately to Severely Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Vedolizumab and Upadacitinib Efficacy and Safety in Adults with Moderate to Severe Crohn's Disease: A Randomized, Double-Blind, Phase 3b Study
- Efficacy and Safety of RO7790121 in Induction and Maintenance Therapy for Moderately to Severely Active Ulcerative Colitis: A Phase III, Multicenter, Double-Blind Study
Data & Insights
Has run more than one trial at 125 of 304 partner sites.
Specializations
Inflammatory Bowel Disease Research
The investigator specializes in treating inflammatory bowel diseases, with particular emphasis on both Crohn's Disease and Ulcerative Colitis in their moderate to severe forms.
- Combination Therapy Approaches
- Advanced Treatment Protocols
- Long-term Disease Management
Key focus includes investigating novel therapeutic combinations for enhanced treatment outcomes in inflammatory bowel conditions.
Therapeutic Innovation
Expertise in evaluating novel biological therapies including guselkumab, golimumab, risankizumab, and vedolizumab for gastrointestinal disorders.
- Biological Therapy Assessment
- Treatment Response Evaluation
- Therapeutic Drug Monitoring
Active involvement in assessing innovative treatment approaches for inflammatory bowel conditions.
Clinical Management
Focused on developing maintenance therapy strategies and evaluating long-term treatment efficacy in chronic gastrointestinal conditions.
- Disease Activity Assessment
- Treatment Optimization
- Patient Response Monitoring
Specializes in managing complex cases requiring advanced therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.